Metabolic syndrome and cardiometabolic risk

An update

Guido Grassi, Gino Seravalle, Fosca Quarti-Trevano, Raffaella Dell'ro, Michele Bombelli, Giuseppe Mancia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Several lines of evidence show that metabolic syndrome represents an important therapeutic challenge for the forthcoming years. This is because of the epidemic burden of this multifaceted disease, the adverse impact on cardiovascular risk, as well as the problems posed in its management. This paper will provide an up-to-date report on metabolic syndrome and cardiometabolic risk, focusing in particular on the epidemiological profile of the disease, the impact on risk profile and target organ damage as well as some of the main pathophysiological features of the condition. The general therapeutic recommendations, provided by the 2007 European Society of Hypertension/European Society of Cardiology Guidelines, will be briefly discussed.

Original languageEnglish
Pages (from-to)7-16
Number of pages10
JournalBlood Pressure
Volume18
Issue number1-2
DOIs
Publication statusPublished - 2009

Fingerprint

Guidelines
Therapeutics

Keywords

  • Antihypertensive treatment
  • Blood pressure
  • Cardiovascular risk
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Metabolic syndrome and cardiometabolic risk : An update. / Grassi, Guido; Seravalle, Gino; Quarti-Trevano, Fosca; Dell'ro, Raffaella; Bombelli, Michele; Mancia, Giuseppe.

In: Blood Pressure, Vol. 18, No. 1-2, 2009, p. 7-16.

Research output: Contribution to journalArticle

Grassi, G, Seravalle, G, Quarti-Trevano, F, Dell'ro, R, Bombelli, M & Mancia, G 2009, 'Metabolic syndrome and cardiometabolic risk: An update', Blood Pressure, vol. 18, no. 1-2, pp. 7-16. https://doi.org/10.1080/08037050802677695
Grassi, Guido ; Seravalle, Gino ; Quarti-Trevano, Fosca ; Dell'ro, Raffaella ; Bombelli, Michele ; Mancia, Giuseppe. / Metabolic syndrome and cardiometabolic risk : An update. In: Blood Pressure. 2009 ; Vol. 18, No. 1-2. pp. 7-16.
@article{fb55d86603de4cdcb08a7d6e03653e56,
title = "Metabolic syndrome and cardiometabolic risk: An update",
abstract = "Several lines of evidence show that metabolic syndrome represents an important therapeutic challenge for the forthcoming years. This is because of the epidemic burden of this multifaceted disease, the adverse impact on cardiovascular risk, as well as the problems posed in its management. This paper will provide an up-to-date report on metabolic syndrome and cardiometabolic risk, focusing in particular on the epidemiological profile of the disease, the impact on risk profile and target organ damage as well as some of the main pathophysiological features of the condition. The general therapeutic recommendations, provided by the 2007 European Society of Hypertension/European Society of Cardiology Guidelines, will be briefly discussed.",
keywords = "Antihypertensive treatment, Blood pressure, Cardiovascular risk, Metabolic syndrome, Obesity",
author = "Guido Grassi and Gino Seravalle and Fosca Quarti-Trevano and Raffaella Dell'ro and Michele Bombelli and Giuseppe Mancia",
year = "2009",
doi = "10.1080/08037050802677695",
language = "English",
volume = "18",
pages = "7--16",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Metabolic syndrome and cardiometabolic risk

T2 - An update

AU - Grassi, Guido

AU - Seravalle, Gino

AU - Quarti-Trevano, Fosca

AU - Dell'ro, Raffaella

AU - Bombelli, Michele

AU - Mancia, Giuseppe

PY - 2009

Y1 - 2009

N2 - Several lines of evidence show that metabolic syndrome represents an important therapeutic challenge for the forthcoming years. This is because of the epidemic burden of this multifaceted disease, the adverse impact on cardiovascular risk, as well as the problems posed in its management. This paper will provide an up-to-date report on metabolic syndrome and cardiometabolic risk, focusing in particular on the epidemiological profile of the disease, the impact on risk profile and target organ damage as well as some of the main pathophysiological features of the condition. The general therapeutic recommendations, provided by the 2007 European Society of Hypertension/European Society of Cardiology Guidelines, will be briefly discussed.

AB - Several lines of evidence show that metabolic syndrome represents an important therapeutic challenge for the forthcoming years. This is because of the epidemic burden of this multifaceted disease, the adverse impact on cardiovascular risk, as well as the problems posed in its management. This paper will provide an up-to-date report on metabolic syndrome and cardiometabolic risk, focusing in particular on the epidemiological profile of the disease, the impact on risk profile and target organ damage as well as some of the main pathophysiological features of the condition. The general therapeutic recommendations, provided by the 2007 European Society of Hypertension/European Society of Cardiology Guidelines, will be briefly discussed.

KW - Antihypertensive treatment

KW - Blood pressure

KW - Cardiovascular risk

KW - Metabolic syndrome

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=67650180128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650180128&partnerID=8YFLogxK

U2 - 10.1080/08037050802677695

DO - 10.1080/08037050802677695

M3 - Article

VL - 18

SP - 7

EP - 16

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - 1-2

ER -